In addition, it has been reported that it is possible to converse basal-like breast cancers into a hormone receptor-positive state that conferred sensitivity to endocrine therapy in previously impervious tumors by genetic or pharmacological intervention with PDGF-CC activity in mouse models [55]. This evidence concerns the gene NR4A1 and breast carcinoma.